Story

Oxford Biomedica Slashes 2026 Revenue Forecast by 17% on Client Delays

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Oxford Biomedica Slashes 2026 Revenue Forecast by 17% on Client Delays
Text size
Background

Oxford Biomedica has significantly lowered its fiscal 2026 revenue and profitability guidance, citing widespread delays in client orders and a slower-than-expected integration of a key U.S. facility. The U.K.-based gene and cell therapy company announced a roughly 17% reduction to its revenue forecast, signaling headwinds from shifting customer strategies.

Revised Financial Outlook

The company adjusted its forward-looking financial targets, which now stand substantially below previous expectations and current market consensus. The revised guidance points to a notable slowdown in anticipated growth.

  • 2026 Revenue: The new forecast is for £180-200 million, a sharp decrease from the prior range of £220-240 million.
  • 2026 Adjusted EBITDA Margin: The outlook was lowered to mid-single digits from a previous target of approximately 10%.

According to the company, the revised revenue midpoint is approximately 17% below current consensus estimates of £228 million. The new margin guidance, assuming a 5% margin, implies a potential 57% reduction from what analysts had been expecting.

Client Behavior and Operational Delays

Sample IUX Markets – In-articleAd

Oxford Biomedica attributed the guidance cut to several factors, primarily related to client ordering patterns. The company reported program deferrals and timeline delays stemming from clients' strategic decisions and clinical data outcomes. A change in procurement strategy at a larger client has also postponed order placement.

Furthermore, the company noted that several customers have adopted a staged approach to ordering work packages, which extends the time it takes to recognize the full value of signed contracts. Operationally, the integration of its Durham, North Carolina facility has progressed about six months more slowly than anticipated, though the site has now completed its first GMP run and is reportedly back on track.

Forward Guidance and H1 Performance

Despite the near-term challenges, Oxford Biomedica maintained its fiscal 2027 revenue growth guidance of 25-30%. However, it adjusted the corresponding 2027 adjusted EBITDA margin target to double-digit percentages, down from a previous goal of exceeding 20%, citing reduced revenue absorption.

In a preliminary update, the company reported that first-half 2026 revenues grew approximately 9% year-over-year to around £80 million. It also noted strong commercial momentum, having signed 17 new clients in the period, which is 30% more than in all of fiscal 2025. The company will report its full first-half results on September 22.

Read next

More on Stocks
Back to latest news

LATEST